February 3rd 2023
The Phase 2 SPECTRA clinical trial will assess 4D-150 in patients with DME.
Sailing study and extension study: Superiority of conbercept over laser in DME
November 1st 2022The Sailing study was a 12-month, 18-center, randomized, double-masked, double-sham, parallel-controlled, phase 3 trial that was conducted in China and included eyes with center-involved DME that were randomly assigned to undergo either laser photocoagulation followed by as-needed sham intravitreal injections or sham laser photocoagulation followed by as-needed 0.5 mg intravitreal injections of conbercept.
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
European Commission approves faricimab for treatment of wet AMD, DME
September 19th 2022Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy
September 10th 2022Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
First patient enrolled in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
September 8th 2022The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
Permanent J-code granted for triamcinolone acetonide injectable suspension from Bausch + Lomb
June 22nd 2022The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
Phase 2 INTEGRAL trial: THR-689 fails to meet primary endpoints in eyes with DME, will not advance
May 10th 2022According to the company, the trial did not demonstrate efficacy on the key clinical endpoints. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of DME.
Trial to study treatment of DME in underrepresented patients begins
April 11th 2022The trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations, ie, Black, Hispanic, Latin American, and Indigenous people.
Outcomes of anti-VEGF therapy for retinal diseases altered by COVID-19 lockdown
April 8th 2022Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.